Jul 11 ​​(.) – India’s Biocon Ltd received regulatory approval for its drug Itolizumab to be used in coronavirus-infected patients suffering from moderate to severe respiratory distress, the biopharmaceutical company said in a statement on Saturday.

The drug, which is also used to cure psoriasis, was approved by the General Drug Controller of India (DCGI) for use in the country.

« The randomized control trial indicated that all Itolizumab-treated patients responded positively and recovered, » said Kiran Mazumdar-Shaw, CEO of Biocon.

The control group that did not receive Itolizumab sadly suffered deaths, it said, adding that the « first of its kind » medicine will save lives and help reduce the death rate in India.

Clinical studies using the drug are being closely watched as countries seek treatments for the disease that has infected more than 820,000 people and killed more than 22,000 in India.

India recorded 27,114 cases of coronavirus in the last 24 hours. The coronavirus case count is the third-largest outbreak, behind only the United States and Brazil in confirmed infections. (Report by Aftab Ahmed Edited in Spanish by Javier López de Lérida)